Literature DB >> 10398899

Intrahepatic cholangiocarcinoma in Thailand.

T Uttaravichien1, V Bhudhisawasdi, C Pairojkul, A Pugkhem.   

Abstract

Intrahepatic cholangiocarcinoma is defined as adenocarcinoma originating from bile ductules and segmental and lobar intrahepatic ducts. Four types of surgical pathology have been identified in the Khon Kaen endemic area in Thailand: peripheral, type I; intermediate, type II; central, type III; and diffuse, type IV. We report our experience with intrahepatic cholangiocarcinoma with emphasis on the surgical pathology, operative procedure, and associated survival time. We reviewed the records of patients treated for cholangiocarcinoma at Srinagarind Hospital from January 1, 1992 to February 28, 1997. There was a total of 411 patients, and 138 were intrahepatic and non-jaundiced. Tumors in the proximity of the gray zone i.e., portal, periportal with jaundice, were excluded. Patient profiles, surgical pathology, operative procedure, postoperative morbidity, and mortality were recorded. The data were analyzed using Kaplan-Meier survival curves. Of the 138 patients with intrahepatic disease who were non-jaundiced, 116 had type I, 10 had type II-III, and 12 had type IV. The wear ages of the patients were: 53.0, SE 9.2 years in type I; 57.1, SE 4.6 years in type II-III, and 50.2, SE 9.2 years in type IV. The male-to-female ratios in the three groups were 1.4 : 1, 1.5 : 1, and 5 : 1, respectively. The mean survival times in the three groups were 556, SE 63 days 374, SE 149 days and 97, SE 35 days. Most of the surgical procedures were tumor excisions (108/138). Right hepatectomy was performed in 63 patients, extended right hepatectomy in 8, left hepatectomy in 18, and extended left hepatectomy in 1. Palliative procedures were performed in the other patients because tumors were in both lobes. The mean survival time was 582 days (SE, 75), for right lobe surgery; 458 days (SE, 89) for left lobe surgery; and 127 days (SE, 58) for the other procedures. Mean survival time was 1039 days (SE, 201) in tumor stage III, 773 days (SE, 123) in stage IVa, and 382 days (SE, 60) in stage IVb. There were no significant differences in survival time according to age or sex. The results of surgery in type I and type II-III were better than the results in type IV. Survival time after right hepatectomy was better than that after left hepatectomy, although without statistical significance, but survival time was significantly better after both operations than after palliative procedures. The results of surgery according to pathological staging showed that survival time in stage III was better than that in either stage IVa or IVb, but only the difference from stage IVb was significant.

Entities:  

Mesh:

Year:  1999        PMID: 10398899     DOI: 10.1007/s005340050095

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  20 in total

1.  Down-regulated expression of HSP70 in correlation with clinicopathology of cholangiocarcinoma.

Authors:  Sirintip Boonjaraspinyo; Thidarut Boonmars; Sasithorn Kaewkes; Porntip Laummaunwai; Somchai Pinlaor; Watchalin Loilome; Puangrat Yongvanit; Zhiliang Wu; Anucha Puapairoj; Vajarabhongsa Bhudhisawasdi
Journal:  Pathol Oncol Res       Date:  2011-07-13       Impact factor: 3.201

2.  Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma.

Authors:  Ponlapat Yonglitthipagon; Chawalit Pairojkul; Yaovalux Chamgramol; Alex Loukas; Jason Mulvenna; Jeffrey Bethony; Vajarabhongsa Bhudhisawasdi; Banchob Sripa
Journal:  Hum Pathol       Date:  2012-03-24       Impact factor: 3.466

3.  Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells.

Authors:  Benjaporn Buranrat; Auemduan Prawan; Upa Kukongviriyapan; Sarinya Kongpetch; Veerapol Kukongviriyapan
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

4.  Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma.

Authors:  Jongkonnee Thanasai; Temduang Limpaiboon; Patcharee Jearanaikoon; Banchob Sripa; Chawalit Pairojkul; Srisurang Tantimavanich; Masanao Miwa
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

5.  Amplification of chromosome 21q22.3 harboring trefoil factor family genes in liver fluke related cholangiocarcinoma is associated with poor prognosis.

Authors:  Kanuengnuch Muenphon; Temduang Limpaiboon; Patcharee Jearanaikoon; Chawalit Pairojkul; Banchob Sripa; Vajarabhongsa Bhudhisawasdi
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

6.  Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.

Authors:  Nisana Tepsiri; Liengchai Chaturat; Banchob Sripa; Wises Namwat; Sopit Wongkham; Vajarabhongsa Bhudhisawasdi; Wichittra Tassaneeyakul
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

7.  Up-regulation of annexin A2 in cholangiocarcinoma caused by Opisthorchis viverrini and its implication as a prognostic marker.

Authors:  Ponlapat Yonglitthipagon; Chawalit Pairojkul; Yaovalux Chamgramol; Jason Mulvenna; Banchob Sripa
Journal:  Int J Parasitol       Date:  2010-05-21       Impact factor: 3.981

8.  Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma.

Authors:  Kanuengnuch Kosriwong; Trevelyan R Menheniott; Andrew S Giraud; Patcharee Jearanaikoon; Banchob Sripa; Temduang Limpaiboon
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

Review 9.  Cholangiocarcinoma: lessons from Thailand.

Authors:  Banchob Sripa; Chawalit Pairojkul
Journal:  Curr Opin Gastroenterol       Date:  2008-05       Impact factor: 3.287

10.  Clinicopathological Significance of Osteopontin in Cholangiocarcinoma Cases.

Authors:  Marut Laohaviroj; Yaovalux Chamgramol; Chawalit Pairojkul; Jason Mulvenna; Banchob Sripa
Journal:  Asian Pac J Cancer Prev       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.